# GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma

> **NCT05668884** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 93 (estimated)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab

## Key facts

- **NCT ID:** NCT05668884
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-18
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 93 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05668884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05668884, "GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05668884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*